{"id":"shr-1905-injection","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pyrexia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SHR-1905 Injection works by binding to PD-1, a protein on the surface of T cells, preventing its interaction with its ligands PD-L1 and PD-L2, and thus enhancing the immune response against cancer cells.","oneSentence":"SHR-1905 Injection is a monoclonal antibody targeting PD-1.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:21.687Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT07211542","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis","status":"RECRUITING","sponsor":"Guangdong Hengrui Pharmaceutical Co., Ltd","startDate":"2025-11-07","conditions":"Moderate-to-severe Atopic Dermatitis","enrollment":75},{"nctId":"NCT06786455","phase":"PHASE2","title":"Pharmacokinetics, Pharmacodynamics, Safety, and Preliminary Efficacy of Subcutaneous Injection of SHR-1905 in Adolescent Asthmatic Subjects - an Open-label, Single-dose Phase II Clinical Study","status":"COMPLETED","sponsor":"Guangdong Hengrui Pharmaceutical Co., Ltd","startDate":"2025-01-23","conditions":"Adolescent Asthma","enrollment":9},{"nctId":"NCT07132827","phase":"PHASE3","title":"Efficacy and Safety of SHR-1905 Injection in Subjects With Chronic Rhinosinusitis With Nasal Polyps","status":"RECRUITING","sponsor":"Guangdong Hengrui Pharmaceutical Co., Ltd","startDate":"2025-08-28","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":280},{"nctId":"NCT07098403","phase":"PHASE3","title":"A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma","status":"RECRUITING","sponsor":"Guangdong Hengrui Pharmaceutical Co., Ltd","startDate":"2025-09-03","conditions":"Asthma","enrollment":408},{"nctId":"NCT04905602","phase":"PHASE1","title":"A Trial of SHR-1905 in Healthy Subjects and Subjects With Mild Asthma","status":"COMPLETED","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2021-06-15","conditions":"Asthma","enrollment":86},{"nctId":"NCT05891483","phase":"PHASE2","title":"Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Hengrui Pharmaceutical Co., Ltd","startDate":"2023-09-04","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":114}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SHR-1905 Injection","genericName":"SHR-1905 Injection","companyName":"Guangdong Hengrui Pharmaceutical Co., Ltd","companyId":"guangdong-hengrui-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SHR-1905 Injection is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}